NCT06685354
Sequential T and I With H101 Via HAI for BCLC C Stage HCC: A Prospective Single-Center Single-Arm Pilot Study
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Minor Changed Registry marked status Unknown (sponsor has not verified the record since Jun 2024); last known: Not Yet Recruiting
- Study First Submitted
- Minor: routine updates
Endpoints
Primary
Objective response rate (ORR)
Timeframe: Generally, the ORR is assessed for each participant every two treatment cycles(each cycle is 3 weeks).
Secondary (4)
Disease control rate (DCR)
Duration of response (DoR)
Progression-Free Survival (PFS)
Overall Survival (OS)
Arms and interventions
experimental groupExperimental
The participants will receive hepatic arterial infusion of recombinant human adenovirus type 5 injection in combination with first-line targeted and immunotherapy as recommended by the 2024 primary liver cancer treatment guidelines.
Drugs: hepatic arterial infusion of recombinant human type 5 adenovirus
Sites
1 site in 1 country
- The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer HospitalZhengzhou, Henan, China